A 56-year-old man with ischaemic heart disease and heart failure with reduced ejection fraction (LVEF 30%) is on maximally tolerated ACE inhibitor, beta blocker and mineralocorticoid receptor antagonist. He remains NYHA class II-III. According to contemporary guideline-directed therapy, what additional class of drug should be considered?